Chicago, IL – According to filings with the U.S. Securities and Exchange Commission, Dystrogen Therapeutics is raising $5,000,000.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, Kris Siemionow played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Dystrogen Therapeutics

Dystrogen Therapeutics is a clinical-stage life sciences company committed to developing personalized therapies for rare genetic diseases. The company has two technology platforms, which focus on treating patients with rare diseases such as Duchenne muscular dystrophy, sickle cell anemia, and neurodegenerative disorders such as Huntington’s disease.

To learn more about Dystrogen Therapeutics, visit http://dystrogen.com/

Contact:
Kris Siemionow, Chief Executive Officer
216-410-1829
https://www.linkedin.com/in/krissiemionow/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved